Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;5(2):161-172.
doi: 10.1007/s40123-016-0065-3. Epub 2016 Sep 12.

Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months

Steven D Vold  1 , Lilit Voskanyan  2 , Manfred Tetz  3 , Gerd Auffarth  4 , Imran Masood  5 , Leon Au  6 , Iqbal Ike K Ahmed  7 , Hady Saheb  8
Affiliations

Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months

Steven D Vold et al. Ophthalmol Ther. 2016 Dec.

Erratum in

Abstract

Purpose: To examine outcomes through 36 months in phakic eyes with newly diagnosed primary open-angle glaucoma (POAG) naïve to therapy randomized to treatment with two trabecular micro-bypass stents or topical prostaglandin.

Methods: Subjects with POAG naïve to therapy, with intraocular pressure (IOP) ≥21 and ≤40 mmHg, were randomized to implantation of two stents or travoprost. Additional medication was to be prescribed post-treatment for elevated IOP or glaucomatous optic nerve findings. Of 101 randomized subjects, 100 subjects were followed for 24 months and 73 subjects were followed for 36 months. Follow-up on all subjects is ongoing.

Results: In this randomized cohort of 101 POAG subjects, 54 subjects underwent 2-stent surgery and 47 received topical travoprost. Mean pre-treatment IOP was 25.5 ± 2.5 mmHg in stent-treated eyes and 25.1 ± 4.6 mmHg in medication-treated eyes. By 3 years, mean IOP was 14.6 mmHg in stent eyes (with medication added in 6 eyes) and 15.3 mmHg in travoprost eyes (with a second medication added in 11 eyes). In the subset of eyes that did not require additional medical therapy, mean IOP was 14.5 mmHg and 15.7 mmHg in the respective groups. Ninety-one percent of stent eyes had 3-year IOP ≤18 mmHg without additional therapy (62% ≤ 15 mmHg) and 79% of travoprost eyes had 3-year IOP ≤18 mmHg (21% ≤ 15 mmHg). Safety was favorable in both groups.

Conclusions: In this prospective, randomized comparison of subjects with newly diagnosed POAG naïve to therapy, substantial IOP reduction with a favorable low complication rate was shown through 3 years after either 2 trabecular stents implanted as the sole procedure or topical travoprost therapy. These data suggest 2-stent implantation may be a viable initial treatment option comparable to topical prostaglandin in newly diagnosed POAG patients.

Trial registration: ClinicalTrials.gov identifier, NCT01443988.

Funding: Glaukos Corporation, Laguna Hills, CA.

Keywords: Glaucoma; IOP; MIGS; POAG; Prostaglandin; Trabecular bypass.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean IOP (mmHg) and number of subjects through 3 years, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 2
Fig. 2
Mean IOP (mmHG) and number of subjects through 3 years in Eyes without additional medical therapy, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 3
Fig. 3
Proportional analysis of post-treatment IOP, percent ≤15, ≤18 mmHg without additional therapy, available eyes of randomized cohort*. IOP intraocular pressure
Fig. 4
Fig. 4
Proportional analysis of BCVA through 3 years, available eyes of randomized cohort*. BCVA best-corrected visual acuity, PRE preoperative
See this image and copyright information in PMC

References

    1. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–S36. doi: 10.1016/j.ophtha.2009.06.024. - DOI - PubMed
    1. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–1316. doi: 10.1016/j.ophtha.2015.03.026. - DOI - PMC - PubMed
    1. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137:3–12. doi: 10.1016/j.ajo.2003.10.035. - DOI - PubMed
    1. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606. doi: 10.1016/j.ajo.2005.04.051. - DOI - PubMed
    1. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS) Invest Ophthalmol Vis Sci. 2007;48:5052–5057. doi: 10.1167/iovs.07-0290. - DOI - PubMed

Associated data

LinkOut - more resources